Quantcast

Latest Islets of Langerhans Stories

2008-09-03 12:00:06

Research and Markets (http://www.researchandmarkets.com/research/d99eac/competitor_analysi) has announced the addition of the "Competitor Analysis: Emerging Diabetes Drugs" report to their offering. Emerging diabetes drugs consider beta cell mass and function as an important target The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum This...

2008-08-26 18:00:15

Launching a counter-attack on the immune response that causes insulin-dependent diabetes may provide a revolutionary new way of treating the disease, research has shown. Scientists have found a way to isolate and kill defective immune system cells that wipe out insulin-producing cells in the pancreas. Type 1 diabetes is an autoimmune disease in which the body's "insulin factory" - pancreatic islet cells - is gradually destroyed by specialised white blood cells called "killer" T-cells....

2008-08-20 09:01:30

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, has appointed Brian D. Conn to the positions of Vice President Corporate Finance and Chief Financial Officer. Mr. Conn has served as a financial executive in high growth companies for over twenty years. He has extensive experience with M&A and capital transactions. Since 2000, Mr. Conn has held executive positions,...

2008-08-13 15:01:02

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report on the Company's presentation at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet's Senior Director and Vice President of R&D,...

2008-07-17 00:00:35

Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today announced that Professor Bob Elliott, Medical Director of LCT, will host a seminar on Friday, August 8, 2008, in Auckland, New Zealand for world leading medical scientists and specialists to discuss current developments with porcine islet transplant technologies. The one day meeting brings together experts with many years experience who are developing methods for delivering insulin producing cells to patients with insulin...

2008-07-14 09:00:14

Tissera, Inc. (OTCBB:TSSR) reports that on July 8, 2008, it has entered into a bridge loan agreement with an accredited investor, who was a participant in the Company's December 2006 fund raising. The terms of this agreement are detailed in a separate Form 8-K report to the United States Securities and Exchange Commission. As part of the initial closing of this agreement, a loan in the sum of $200,000, with net proceeds amounting to $170,000, has been received by the Company. The current...

2008-07-02 09:01:03

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report recent safety and efficacy data. To date, MicroIslet has seen no adverse events attributable to MicroIslet-P(TM) in its animal models. The Company has tested hundreds of rodents and is currently completing a trial with nineteen non-human primates. Eighteen of the nineteen have been tested, and the last...

2008-06-25 09:02:22

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved $2 million in milestone payments from the Juvenile Diabetes Research Foundation (JDRF) for progress made on a Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell (MSC) therapy, for patients recently diagnosed with type 1 diabetes. The payments were triggered when Osiris accomplished certain clinical and regulatory milestones including initiating patient treatments. "Due to the long-term effects of...

bedca6f06d9a4cbce582036a0eb50c5b
2008-05-12 10:41:41

Scientists at Washington University School of Medicine in St. Louis working with diabetic mice have examined in unprecedented detail the immune cells long thought to be responsible for type 1 diabetes.Researchers were able to examine the immune cells from isolated insulin-making structures in the pancreas known as the islets of Langerhans. They caught the immune cells, known as dendritic cells, "red-handed" carrying insulin and fragments of insulin-producing cells known as beta cells. This...

2008-04-04 15:00:09

Kinexum Metabolics, Inc. (KMI) announced two abstracts will be presented on INGAP Peptide at the Keystone Symposia on Islet and Beta Cell Biology to be held April 6-10, 2008. These two studies demonstrate important new data to advance the development of INGAP Peptide as a treatment to regenerate fully functioning islet cells that can restore insulin secretion for Type 1 diabetes patients. "We are encouraged by these new studies and believe they demonstrate great potential for INGAP Peptide...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related